Inhibitory effects on Epstein-Barr virus activation of anthraquinones: correlation with redox potentials. 1997

J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
Faculty of Pharmaceutical Sciences, Kobe Pharmaceutical University, Higashinada, Japan.

The redox potentials have been determined for nine anthraquinones in phosphate buffer at pH 7.2 by means of cyclic voltammetry. A definite correlation has been found between the redox potentials and the inhibitory effects of the anthraquinones on the EBV-EA activation. It has further been shown that the correlation can be made better by introducing an electronic property, i.e. the atomic charge at O12 as an additional parameter.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004563 Electrochemistry The study of chemical changes resulting from electrical action and electrical activity resulting from chemical changes. Electrochemistries
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000880 Anthraquinones Compounds based on ANTHRACENES which contain two KETONES in any position. Substitutions can be in any position except on the ketone groups. Anthracenedione,Anthracenediones,Anthranoid,Anthraquinone,Anthraquinone Compound,Anthraquinone Derivative,Dianthraquinones,Dianthrones,Anthranoids,Anthraquinone Compounds,Anthraquinone Derivatives,Compound, Anthraquinone,Derivative, Anthraquinone
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral

Related Publications

J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
July 2005, Cancer letters,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
November 2003, Cancer letters,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
August 2004, Cancer letters,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
May 2008, Cancer letters,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
September 2006, Cancer letters,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
August 1995, Cancer letters,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
February 2003, Bioorganic & medicinal chemistry,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
July 1992, Cancer letters,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
April 1997, Chemical & pharmaceutical bulletin,
J Koyama, and K Tagahara, and T Osakai, and Y Tsujino, and S Tsurumi, and H Nishino, and H Tokuda
December 1995, Planta medica,
Copied contents to your clipboard!